// App-Quantinova.ai

5084 : KMT2D and PIK3CA mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer

Researchers

Presenter

  • Xue Wang

Principal Investigators

  • Feng Du

  • Jian Yue

  • Yiran Si

  • Lina Cui

  • Bei Zhang

  • Xiaochen Zhao

  • Binghe Xu

  • Peng Yuan

Medical Centers

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • The Medical Department, 3D Medicines Inc., Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Epirubicin

  • Paclitaxel

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01150513

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved